Document Detail

Significance of antiplatelet therapy in emergency myocardial infarction treatment.
MedLine Citation:
PMID:  24799926     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Antiplatelet drugs play a crucial role in the treatment of patients with myocardial infarction, particularly in association with percutaneous coronary intervention. Their main advantage is the reduction of adverse ischemic incidents and the major disadvantage is the increase in the frequency of hemorrhages. Thus, the choice of appropriate drug depends on the right risk assessment of the development of these complications in individual patients. The aim of this article is to provide an update of antiplatelet therapy in emergency myocardial infarction treatment. Currently, the most important role in the process of platelet inhibition is played by ADP P2Y12 blockers: clopidogrel, prasugrel and ticagrelor. Clopidogrel and prasugrel belong to thienopyridines, and ticagrelor, a drug of irreversible action, is an analogue of adenosine triphosphate. By 2011 clopidogrel, alongside aspirin, had the highest recommendations of world cardiology associations for acute coronary syndrome treatment. The position on clopidogrel was changed following the publication of European Society of Cardiology guidelines for STEMI in 2012 which advocate the administration of acetylsalicylic acid (ASA) and ADP receptor blocker (in combination with ASA). It needs to be stressed that prasugrel and ticagrelor received class IB recommendation, while clopidogrel received only IC. However, the most recent studies aimed at introducing a new generation of antiplatelet drugs of high efficacy in prevention of ischemic incidents and of reversible action: cangrelor and elinogrel, which raise hopes for better prognosis for myocardial infarction patients.
Anna Komosa; Maciej Lesiak; Andrzej Siniawski; Tatiana Mularek-Kubzdela; Stefan Grajek
Related Documents :
3979086 - Effect of varying freezing and thawing rates in experimental cryosurgery.
15693606 - Chemokines in the ischemic myocardium: from inflammation to fibrosis.
16166556 - Exogenous high-mobility group box 1 protein induces myocardial regeneration after infar...
21821526 - Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to ad...
16060696 - Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive...
8302076 - Evaluation of the pulsatility of a new pulsatile left ventricular assist device--the in...
Publication Detail:
Type:  Journal Article; Review     Date:  2014-03-23
Journal Detail:
Title:  Postępy w kardiologii interwencyjnej = Advances in interventional cardiology     Volume:  10     ISSN:  1734-9338     ISO Abbreviation:  Postepy Kardiol Interwencyjnej     Publication Date:  2014  
Date Detail:
Created Date:  2014-05-06     Completed Date:  2014-06-24     Revised Date:  2014-06-24    
Medline Journal Info:
Nlm Unique ID:  101272671     Medline TA:  Postepy Kardiol Interwencyjnej     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  32-9     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pregnancy after myocardial infarction and coronary artery bypass grafting - is it safe?
Next Document:  Beneficial triple-site cardiac resynchronization in a patient supported with an intra-aortic balloon...